Dermatology Times Newsletter

To view this email as a web page, click here.

Clinical Considerations for Derm NPs and PAs

This month’s highlights center on how systemic conditions can have cutaneous signs, using baricitinib to treat itch in moderate to severe AD, and what signs could predict successful treatment of actinic keratosis. Read my comments below, and the stories for further insights! Read my takeaways and the full stories below!
— Joe Gorelick

CLINICAL CONSIDERATIONS

Systemic conditions that can affect skin

As Dermatology NPs and PAs it is essential that we are familiar with hallmark Cutaneous Signs of Systemic disease. Diseases such as Lupus, Dermatomyositis, Gastrointestinal Disease, or an Internal Malignancy may have cutaneous signs or signals that clue us in to a potential systemic process. Read on to learn more about specific cutaneous signs of the diseases listed above and register now for DERM2018 at www.DermNPPA.org to advance your dermatology knowledge and skills.

Less itch and more sleep with baricitinib

Rapid itch reduction was seen as early as one week in this phase 2 data studying Baricitinib for the treatment of Moderate to Severe Atopic Dermatitis (AD). Baricitinib is a once-daily oral Janus kinase (JAK) 1 and 2 inhibitor. The JAK’s will soon be coming to the world of Dermatology specifically in Psoriasis, Psoriatic Arthritis and Atopic Dermatitis. It is important that we become versed in the inflammatory pathways on which JAK inhibition will exert effects. In this article Dr. Silverberg provides a concise description of inflammatory cytokines important to AD such as IL-4, IL-13, IL-31, that are mediated by the JAK/STAT pathway. He suggests that baricitinib may have an added benefits because it directly targets inflammation as well as itch. In clinical studies, baricitinib has also shown to improve the objective signs of AD.

Predictors for successful actinic keratosis treatment

How do you approach the treatment of Actinic Keratoses (AK)? What we know is that we need to treat them because of their potential to become malignant yet we do not know which ones will progress- So we need to treat them all. This study identified key dermatoscopic findings that seem to predict a higher treatment success rate using ingenol mebutate 0.015% for the treatment of AKs on the face. Specifically on the face AKs dermascopically showing a red pseudonetwork, which lack structure and look like red areas intermingled with small roundish white areas, were nearly two times more likely to achieve complete dermoscopic clearance. Brush up on your Dermoscopy skills with a 2-Hour Dermoscopy session at DERM2018 this summer.

JOB OPPORTUNITIES

AZ - Integrated Dermatology

CO - Dermatology Specialists of Boulder

CO - Leavitt Management Group

CT - Integrated Dermatology

FL - Integrated Dermatology

FL - Leavitt Management Group

GA - Leavitt Management Group

IL - Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

MI - Leavitt Management Group

National - Integrated Dermatology

NC - Integrated Dermatology

NJ - Integrated Dermatology

NY - Integrated Dermatology

OR - Cynthia Dreyer MD

PA - Leavitt Management Group

PA - Integrated Dermatology

RI - Leavitt Management Group

TN - Integrated Dermatology

TX - Company Confidential

VA - Integrated Dermatology

WA - Integrated Dermatology

WY - Leavitt Management Group

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT